PROCEPT BioRobotics
PROCEPT BioRobotics' revenue rose 37.2% to $308 million in fiscal 2025. Its operating margin was −33.7%, up from −43.0% a year earlier. Free cash flow was −$58 million. The diluted share count rose 6.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What PROCEPT BioRobotics does
PROCEPT BioRobotics makes surgical robots for urology, the care of the urinary system. Its first focus is benign prostatic hyperplasia, or BPH, a non-cancerous enlargement of the prostate that can block the flow of urine. Hospitals buy its robotic systems, which use a single-use handpiece to carry out Aquablation therapy. The therapy combines imaging, treatment planning, a robot and a heat-free waterjet to remove prostate tissue.
The company earns money from selling its robotic systems, the AquaBeam and the HYDROS, and from the disposable handpieces used in each procedure. Its revenue depends mainly on these two. It sells through its own team and, in some markets, through third-party distributors. It says it competes with other surgical treatments for BPH, with drug therapy and with larger companies.
The company began developing the AquaBeam system in 2009. It says its clinical evidence includes clinical studies and many peer-reviewed publications. It has a loan agreement that sets operating and financial requirements.
Its biggest risks, as it describes them
- A history of net losses, with more losses expected and no certainty of lasting profitability.
- Dependence on sales of its robotic systems and the single-use handpieces used with them.
- Hospitals, surgeons and patients may not accept its products widely enough.
- Insurers may not cover or pay for its procedures at adequate levels.
- Reliance on third-party and single-source suppliers and contract manufacturers.
Income statement
PROCEPT BioRobotics lost money in fiscal 2025: a net loss of $96 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 304 | 222 | 257 | 334 | 286 |
| Debt incl. finance leases | 50 | 51 | 51 | 52 | 52 |
| Net debt (negative means net cash) | −254 | −171 | −206 | −282 | −235 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.3x | 0.2x | 0.1x | 0.1x |
| Interest coverage | −9.3x | −15.6x | −27.3x | −23.1x | −29.0x |
| Current ratio | 20.1x | 7.7x | 7.6x | 9.1x | 6.8x |
| Quick ratio | 19.3x | 6.9x | 6.8x | 8.0x | 5.8x |
Cash flow
Projections
Project PROCEPT BioRobotics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of PROCEPT BioRobotics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 5 of 9 |
| Rule of 40 | −16.3% | 18.7% | 18.3% |
| Altman Z'' | 1.84 | 3.92 | 2.18 |
| Accruals ratio | 0.6% | 1.7% | −8.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 5 of 9 | 5 of 9 |
Compare
Put PROCEPT BioRobotics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| PROCEPT BioRobotics | FY25 | 37.2% | −33.7% | −18.9% | −65.4% | — | 5 | |
| Angiodynamics | FY26 | 9.5% | −12.5% | 0.2% | −24.6% | — | 4 | Compare |
| Tactile Systems Technology | FY25 | 12.5% | 8.9% | 12.3% | 12.6% | −2.3x | 8 | Compare |
| LeMaitre Vascular | FY25 | 13.5% | 27.2% | 29.8% | 25.5% | −2.4x | 5 | Compare |
| STAAR Surgical | FY25 | −23.7% | −38.3% | −16.7% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 8 | 34 | 75 | 136 | 224 | 308 |
| Revenue growth | — | 346.7% | 117.6% | 81.5% | 64.8% | 37.2% |
| Gross profit | −1 | 16 | 37 | 71 | 137 | 196 |
| Research and development | 16 | 19 | 29 | 48 | 62 | 71 |
| Operating income | −48 | −54 | −81 | −109 | −97 | −104 |
| Net income | −53 | −60 | −87 | −106 | −91 | −96 |
| Diluted EPS (US$) | −14.47 | −3.63 | −1.96 | −2.24 | −1.75 | −1.72 |
| Diluted shares (millions) | 4 | 16 | 44 | 47 | 52 | 56 |
| Cash flow | ||||||
| Cash from operations | −48 | −57 | −80 | −108 | −99 | −49 |
| Capital expenditure | 0 | 1 | 3 | 25 | 4 | 9 |
| Free cash flow | −49 | −58 | −83 | −133 | −104 | −58 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 10 | 19 | 32 | 48 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 100 | 304 | 222 | 257 | 334 | 286 |
| Debt incl. finance leases | 49 | 50 | 51 | 51 | 52 | 52 |
| Total assets | 126 | 337 | 309 | 405 | 534 | 508 |
| Total liabilities | 65 | 70 | 112 | 124 | 132 | 142 |
| Shareholders' equity | −183 | 267 | 197 | 281 | 402 | 366 |
| Margins and ratios | ||||||
| Gross margin | −16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating margin | −619.4% | −157.1% | −107.6% | −80.2% | −43.0% | −33.7% |
| Net margin | −687.0% | −173.6% | −116.2% | −77.8% | −40.7% | −31.0% |
| Free cash flow margin | −629.5% | −168.0% | −110.7% | −97.8% | −46.2% | −18.9% |
| Rule of 40 (growth + FCF margin) | — | 178.7% | 6.9% | −16.3% | 18.7% | 18.3% |
| Return on capital | — | — | — | −170.3% | −78.3% | −65.4% |
| Return on equity | — | −142.2% | −37.5% | −44.3% | −26.8% | −24.9% |
| Return on assets | — | −25.9% | −27.0% | −29.7% | −19.5% | −18.3% |
| Net debt to EBITDA | — | — | — | — | — | — |